Literature DB >> 21142819

The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities.

Helle Kristiansen1, Hans Henrik Gad, Signe Eskildsen-Larsen, Philippe Despres, Rune Hartmann.   

Abstract

The 2'-5' oligoadenylate synthetases (OAS) are interferon-induced antiviral enzymes that recognize virally produced dsRNA and initiate RNA destabilization through activation of RNase L within infected cells. However, recent evidence points toward several RNase L-independent pathways, through which members of the OAS family can exert antiviral activity. The crystal structure of OAS led to a novel insight into the catalytic mechanism, and revealed a remarkable similarity between OAS, Polyadenosine polymerase, and the class I CCA-adding enzyme from Archeoglobus fulgidus. This, combined with a variety of bioinformatic data, leads to the definition of a superfamily of template independent polymerases and proved that the OAS family are ancient proteins, which probably arose as early as the beginning of metazoan evolution.

Mesh:

Substances:

Year:  2010        PMID: 21142819     DOI: 10.1089/jir.2010.0107

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  106 in total

Review 1.  New insights into the role of RNase L in innate immunity.

Authors:  Arindam Chakrabarti; Babal Kant Jha; Robert H Silverman
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

2.  Suppressing PARylation by 2',5'-oligoadenylate synthetase 1 inhibits DNA damage-induced cell death.

Authors:  Anna A Kondratova; HyeonJoo Cheon; Beihua Dong; Elise G Holvey-Bates; Metis Hasipek; Irina Taran; Christina Gaughan; Babal K Jha; Robert H Silverman; George R Stark
Journal:  EMBO J       Date:  2020-04-23       Impact factor: 11.598

3.  2'-5'-Oligoadenylate Synthetase-Like Protein Inhibits Respiratory Syncytial Virus Replication and Is Targeted by the Viral Nonstructural Protein 1.

Authors:  Jayeeta Dhar; Rolando A Cuevas; Ramansu Goswami; Jianzhong Zhu; Saumendra N Sarkar; Sailen Barik
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

4.  RNase L triggers autophagy in response to viral infections.

Authors:  Arindam Chakrabarti; Prabar Kumar Ghosh; Shuvojit Banerjee; Christina Gaughan; Robert H Silverman
Journal:  J Virol       Date:  2012-08-08       Impact factor: 5.103

5.  ELTA: Enzymatic Labeling of Terminal ADP-Ribose.

Authors:  Yoshinari Ando; Elad Elkayam; Robert Lyle McPherson; Morgan Dasovich; Shang-Jung Cheng; Jim Voorneveld; Dmitri V Filippov; Shao-En Ong; Leemor Joshua-Tor; Anthony K L Leung
Journal:  Mol Cell       Date:  2019-01-31       Impact factor: 17.970

6.  Recurrent Loss-of-Function Mutations Reveal Costs to OAS1 Antiviral Activity in Primates.

Authors:  Clayton M Carey; Apurva A Govande; Juliane M Cooper; Melissa K Hartley; Philip J Kranzusch; Nels C Elde
Journal:  Cell Host Microbe       Date:  2019-01-31       Impact factor: 21.023

Review 7.  Translation inhibition and stress granules in the antiviral immune response.

Authors:  Craig McCormick; Denys A Khaperskyy
Journal:  Nat Rev Immunol       Date:  2017-06-26       Impact factor: 53.106

Review 8.  Double-Stranded RNA Sensors and Modulators in Innate Immunity.

Authors:  Sun Hur
Journal:  Annu Rev Immunol       Date:  2019-01-23       Impact factor: 28.527

9.  ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.

Authors:  Harini Sooryanarain; Adam J Rogers; Dianjun Cao; Mary Etna R Haac; Yogesh A Karpe; Xiang-Jin Meng
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

10.  Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor.

Authors:  Jianzhong Zhu; Yugen Zhang; Arundhati Ghosh; Rolando A Cuevas; Adriana Forero; Jayeeta Dhar; Mikkel Søes Ibsen; Jonathan Leo Schmid-Burgk; Tobias Schmidt; Madhavi K Ganapathiraju; Takashi Fujita; Rune Hartmann; Sailen Barik; Veit Hornung; Carolyn B Coyne; Saumendra N Sarkar
Journal:  Immunity       Date:  2014-06-12       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.